Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034925.xml
Download PDF
Hamostaseologie 1988; 08(02): 100-101
DOI: 10.1055/s-0038-1659868
DOI: 10.1055/s-0038-1659868
Originalarbeiten
Fibrinolyse und kardioprotektive Therapie
Further Information
Publication History
Publication Date:
25 June 2018 (online)
Zusammenfassung
Nichtselektive ß-Rezeptoren-Blok-kade verlängert die ECLT und vermindert die Aktivität des Gewebe-plasminogenaktivators (3, 4, 7). Selektive ß-Rezeptoren-Blocker verändern die fibrinolytische Aktivität nicht, während Blocker mit ISA entsprechend ihrer ISA-Aktivität die Fibrinolyse beeinflussen. Die Wirkung von Kalziumkanalblockern ist noch nicht ausreichend untersucht. Eine mögliche günstige Wirkung dieser Medikamente auf die fibrinolytische Aktivität bei verschiedenen Gruppen von Patienten kann jedoch nicht ausgeschlossen werden.
-
Literatur
- 1 Bjerre Knudsen J, Gormsen J, Skagen K, Amtorp O. Changes in platelet functions, coagulation and fibrinolysis in uncomplicated cases of acute myocardial infarction. Thromb Haemost 1980; 42: 1513-22.
- 2 Gaffney P.J, Jespersen J, Nieuwenhuizen W. Fibrinolysis and the thrombotic tendency. Thromb Haemost 1984; 52: 96-7.
- 3 Jürgensen H.J, Dalsgaard-Nielsen J, Kjøller E, Gormsen J. Effect of long-term beta-blockade with alprenolol on platelet function and fibrinolytic activity in patients with coronary heart disease. Eur J Pharmacol 1981; 20: 245-50.
- 4 Winther K, Hedman C. Beta-adrenoceptor blockade, platelets and rhéologie factors. Cephalalgia 1986; 6 (Suppl. 05) 33-9.
- 5 Krai J.G, Åblad B, Johnsson G, Korsan-Bengtsen K. Effects of adrenaline and alprenolol on blood coagulation and fibrinolysis in man. Eur J Clin Pharmacol 1971; 3: 144-7.
- 6 Ferguson E.W, Bernier L.L, Banta G.R, Yu-Yahiro J, Schoomaker E.B. Effects of exercise and conditioning on clotting and fibrinolytic activity in men. J Appi Physiol 1987; 62: 1416-21.
- 7 Winther K, Warberg J, Knigge U. The effect of intrinsic sympathomimetic activity on platelet aggregation and fibrinolytic activity. Current Opinion in Cardiology 1987; 23: 1-3.
- 8 Adler B, Gimbrone Jr M.A, Schäfer A.I, Handin R.I. Prostacyclin and -adrenergic catecholamines inhibit arachidonate release and PGI2 synthesis by vascular endothelium. Blood 1981; 58: 514-7.
- 9 Kooista T, Verheijen J.H, Chang G.T.G, van den Berg A.P, van Hinsbergh V.W.M, Rijken D.C, van Zonneveld A.J, Panne-koek H, Kluft C. Regulation of tissue-type plasminogen activator (t-PA) production by human endothelial cells (EC) in culture. Thromb Haemost 1985; 54: 192 (Abstr)
- 10 Winther K, Snorrason K, Knudsen J.B, Medgyesi S. The effect of prostacyclin infusion on tissue plasminogen activator. Thromb Research 1987; 46: 741-5.
- 11 Winther K, Knudsen J.B. Does phosphodiesterase inhibition enhance the fibrinolytic activity. Eigth International Congress on Fibrinolysis. Binder B.R. (ed) Edinburgh : Churchill Livingstone; 1986. Abstr, 206.
- 12 Marsh N, Gaffney P. Some observations on the release of extrinsic and intrinsic plasminogen activators during exercise in man. Haemostasis 1980; 9: 238-47.
- 13 Sengeløv H, Winther K. Platelet function at rest and after exercise during calcium antagonist treatment. Eur Heart J 1987; Suppl 2: 118.
- 14 Rademaker M, Thomas R.H.M, Kirby J.D, Kovacs I.B. Effect of the calcium channel blocker, nifedipine, on haemostasis, clotting, and thrombolysis ex vivo. Thromb Haemost 1987; 58:(Abstr 637).